Emerging trends in the stabilization of amorphous drugs.
about
The Future of Pharmaceutical Manufacturing SciencesCrystallization and phase changes in paracetamol from the amorphous solid to the liquid phaseNew Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin.Size, Stability, and Porosity of Mesoporous Nanoparticles Characterized with Light Scattering.Nanoethosomal formulation of gammaoryzanol for skin-aging protection and wrinkle improvement: a histopathological study.The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.Physical stabilization of low-molecular-weight amorphous drugs in the solid state: a material science approach.Optimising Drug Solubilisation in Amorphous Polymer Dispersions: Rational Selection of Hot-melt Extrusion Processing ParametersInsoluble drug delivery strategies: review of recent advances and business prospects.Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP/VA Amorphous Solid Dispersions.Rational excipient selection for co-amorphous formulations.Stabilisation of an amorphous form of ROY through a predicted co-former interaction.The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles: formulation and characterization.Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin.Preformulation studies on solid self-emulsifying systems in powder form containing magnesium aluminometasilicate as porous carrier.Formulation of gammaoryzanol-loaded nanoparticles for potential application in fortifying food products.Freeze Dried Quetiapine-Nicotinamide Binary Solid Dispersions: A New Strategy for Improving Physicochemical Properties and Ex Vivo Diffusion.Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.Probing the effects of experimental conditions on the character of drug-polymer phase diagrams constructed using Flory-Huggins theory.Long-Term Stability of New Co-Amorphous Drug Binary Systems: Study of Glass Transitions as a Function of Composition and Shelf Time.Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.Solubility and dissolution enhancement strategies: current understanding and recent trends.Crystallization of undercooled liquid fenofibrate.NANOPARTICLES. Production of amorphous nanoparticles by supersonic spray-drying with a microfluidic nebulator.Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution BehaviorsNanostructure and pore size control of template-free synthesised mesoporous magnesium carbonateCo-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and HypercholesterolemiaProperties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage.
P2860
Q26797515-43271693-6312-4E56-B552-7F91288FAB87Q35104491-E1434251-9B7D-4220-B79D-3B7535153158Q35917803-35A70504-EB0F-4299-ABBD-D3440C7EB507Q36260671-CAC21CD5-BC17-40DE-9540-C50BEF4D47A6Q36302108-59419E45-8D04-41A2-956B-0EC7927E5AC6Q38239948-5EE37F03-1A68-4B83-AD6B-436E726770ECQ38257177-FF89D00D-A3F1-4886-8776-F2FBEAC8B4D0Q38619541-23D7D8D8-FA48-4351-B0D9-5AFFBBBA574BQ38637003-D763DFCC-601A-4A14-AC38-24C8F09A433FQ38790753-A5659FE9-08B7-4CD0-B0DE-43F7766EDBC2Q38856865-C7B21EC1-7C66-40C2-A6B6-E09FA2E5E0DCQ38876711-754276F8-C86E-402F-8741-155AC49FC9D3Q39317255-B4842993-D717-43F9-9E8C-381F1823A29CQ40167348-9035590A-04DF-414F-B046-794C65B5353DQ40375864-83307E93-1C8F-49C1-B8DC-6FFE1455B8DFQ41110566-CAE23812-5DA0-4191-AF54-CE2AE9AE05EFQ42012855-A483F535-418D-49AF-B43A-CF085211D8F4Q42353210-30E69027-A104-4D8D-942B-4EC786D6118CQ42646407-6FB4268A-88BB-4E66-B02E-F019AE497F2BQ42936240-3F5B330B-8ED2-4D24-8ED7-9D6BA7FBFDD7Q48244592-54F9E1F4-7A6D-4344-8FCD-EEA421EB8F33Q48898230-DA476D64-8188-4E43-A4C5-CD2A6262D90DQ49092618-E7EBDD67-8C2D-4EAA-BDF6-F3CCDA51DF0BQ50756353-E1875E73-F0C1-403C-88CF-1F896BA7D4B7Q51020710-5D8C216C-D5AC-46CA-990C-3554855CBC79Q51671101-C921A34E-8A9B-4097-BC0D-7BBDFDBDF4CEQ51792669-6C783A67-9803-4712-82BB-B6CA2634CC7DQ57094720-ED02D512-ECA9-4030-A872-1518585F9DB2Q57535431-97DAA5B3-1AEE-4623-9DDD-C9466DBCADA1Q58691868-86FC082F-0854-4801-8C6E-B952B013607BQ59234241-42E101B8-69ED-4724-B5C1-D0859650913F
P2860
Emerging trends in the stabilization of amorphous drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Emerging trends in the stabilization of amorphous drugs.
@en
type
label
Emerging trends in the stabilization of amorphous drugs.
@en
prefLabel
Emerging trends in the stabilization of amorphous drugs.
@en
P50
P1476
Emerging trends in the stabilization of amorphous drugs
@en
P2093
Riikka Laitinen
P356
10.1016/J.IJPHARM.2012.04.066
P407
P577
2012-04-28T00:00:00Z